XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.1
License and Collaboration Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 29, 2021
Feb. 28, 2023
Jan. 31, 2023
Dec. 31, 2022
Aug. 31, 2020
Oct. 31, 2019
Sep. 30, 2019
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2023
Dec. 31, 2021
Jun. 30, 2022
Feb. 28, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Total revenue                 $ 1,826,000 $ 1,694,000        
Deferred revenue, current portion $ 6,675,000       $ 8,156,000 [1]       6,675,000          
Receivable from licensing and collaboration agreements 10,761,000       17,079,000 [1]       10,761,000          
Research and development                 92,861,000 107,649,000        
Allowance for credit losses 0       0       $ 0          
Common Stock                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Shares issued                 8,823,530          
ASC 808                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses                 $ 0 1,200,000        
Helsinn Therapeutics                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Reimbursable payment received         15,000,000.0                  
Close-out plan costs subject to reimbursement                 $ 2,400,000          
Percentage of close-out plan costs, subject to reimbursement                 50.00%          
QED Therapeutics, Inc                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Close-out plan costs       $ 11,000,000.0         $ 3,600,000          
Receivable from licensing and collaboration agreements 9,000,000.0               9,000,000.0          
Close-out plan costs subject to reimbursement                 1,100,000          
QED Therapeutics, Inc | Forecast                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Close-out plan costs                     $ 11,000,000.0      
QED Therapeutics, Inc | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Warrant to purchase percentage             10.00%              
Nonrefundable upfront payment receivable             $ 10,000,000.0              
QED Therapeutics, Inc | Maximum | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Future potential development and sales milestone payments yet to receive             $ 132,500,000              
License and Collaboration Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Unbilled receivables $ 10,400,000       $ 16,800,000       $ 10,400,000          
Percentage of total unbilled receivables 94.10%       97.50%       94.10%          
License and Collaboration Agreement | Helsinn Therapeutics                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Percentage share of global development costs   60.00%                        
License and Collaboration Agreement | BMS                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront payment yet to be received                         $ 90,000,000.0  
Upfront, regulatory and launch milestone payments yet to be received $ 815,000,000.0               $ 815,000,000.0          
License and Collaboration Agreement | QED Therapeutics, Inc                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
License agreement percentage share of profits and losses   50.00%                        
Percentage share of global development costs   40.00%                        
Regulatory and sales-based milestone payments yet to be received                           $ 66,000,000.0
Reimbursable research and development                 18,800,000          
Reimbursable commercial contracted activities                 12,500,000          
License and Collaboration Agreement | QED Therapeutics, Inc | Helsinn Therapeutics | ASC 808                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Research and development                 1,200,000 6,200,000        
License and Collaboration Agreement | Navire Pharma, Inc | BMS                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Milestone payments 0               0          
Initial transaction price for the license and collaboration agreement                 90,000,000.0          
Allocation of transaction price for research and development                 19,800,000          
Allocation of transaction price to licenses                 70,200,000          
Deferred revenue 13,600,000       $ 15,300,000       13,600,000          
Deferred revenue, current portion 6,700,000       8,200,000       6,700,000          
Deferred revenue, noncurrent 6,900,000       7,100,000       6,900,000          
License and Collaboration Agreement | Navire Pharma, Inc | Research and Development Expense | BMS                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Total revenue                 1,700,000          
License and Collaboration Agreement | Receivable from Licensing and Collaboration Agreements                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Receivable from licensing and collaboration agreements 10,800,000       17,100,000       10,800,000          
License Agreement | Helsinn Therapeutics                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Receivable from licensing and collaboration agreements 10,100,000       $ 16,300,000       10,100,000          
License Agreement | LianBio                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Nonrefundable upfront payment receivable           $ 8,000,000.0                
License Agreement | LianBio | License and Services Revenue                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Total revenue                       $ 8,500,000    
License Agreement | Maximum | LianBio                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Future potential development and sales milestone payments yet to receive           $ 382,100,000                
License Agreement | QED Therapeutics, Inc | LianBio | License and Services Revenue                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Total revenue                 0 0        
License Agreement | Navire Pharma, Inc | LianBio | License and Services Revenue                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Total revenue                 0 $ 0        
Foundation Medicine Diagnostics Agreement | QED Therapeutics, Inc | Foundation Medicine, Inc                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Reimbursable payment received 2,000,000.0                          
Receivable from licensing and collaboration agreements       $ 5,300,000                    
Reimbursable remaining commencing installments     $ 11,000,000.0                      
Reimbursable remaining due in eleven equal monthly commencing installments     $ 1,000,000.0                      
Alexion License Agreements | Eidos                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront nonrefundable payment received               $ 25,000,000.0            
Alexion License Agreements | Maximum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Regulatory milestone payment receivable subject to achievement of regulator milestones 30,000,000.0               30,000,000.0          
Alexion Agreements | Eidos                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Total revenue               26,700,000            
Nonrefundable upfront payment receivable               $ 25,000,000.0            
Alexion Agreements | Eidos | Common Stock                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Shares issued               556,173            
Shares issued, price per share               $ 44.95            
Aggregate purchase price               $ 25,000,000.0            
Excess of purchase price over the value of common stock shares $ 1,700,000               $ 1,700,000          
Alexion Agreements | Eidos | Common Stock | The Nasdaq Global Select Market                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Shares issued, price per share               $ 41.91            
Excess of purchase price over the value of common stock shares               $ 1,700,000            
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.